<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>In the therapeutic field of T-cell lymphoma/leukemia, long-term efficacy has not yet reached a satisfactory level, especially for relapsed refractory T-cell hematological disorders. In this study, we experimentally explored the therapeutic potential of chimeric antigen-modified T cells targeting CD4 (CD4-CART). Specific CD4-CART-T cells were constructed and evaluated in vitro and in vivo against CD4+ T-cell malignant hematologic diseases using lentiviral vectors. The cytokine responses during CD4+-CART cell therapy were preliminarily analyzed. The study results showed that the incidence of adverse events associated with CAR-T cell therapy was 73.43%, and the incidence of > grade 2 CRS was 34.36%. All 20 patients achieved a 100% CR rate with guaranteed dose control, and none experienced grade 3 or higher CRS or severe neurotoxicity. This finding validates the effectiveness of novel therapeutic strategies such as CAR-T in combating T-cell malignant hematologic diseases and provides an experimental basis for future treatment.</p>
</abstract>

In the therapeutic field of T-cell lymphoma/leukemia, long-term efficacy has not yet reached a satisfactory level, especially for relapsed refractory T-cell hematological disorders. In this study, we experimentally explored the therapeutic potential of chimeric antigen-modified T cells targeting CD4 (CD4-CART). Specific CD4-CART-T cells were constructed and evaluated in vitro and in vivo against CD4+ T-cell malignant hematologic diseases using lentiviral vectors. The cytokine responses during CD4+-CART cell therapy were preliminarily analyzed. The study results showed that the incidence of adverse events associated with CAR-T cell therapy was 73.43%, and the incidence of > grade 2 CRS was 34.36%. All 20 patients achieved a 100% CR rate with guaranteed dose control, and none experienced grade 3 or higher CRS or severe neurotoxicity. This finding validates the effectiveness of novel therapeutic strategies such as CAR-T in combating T-cell malignant hematologic diseases and provides an experimental basis for future treatment.

Experimental study of CD4-CART cells for the treatment of CD4-positive T-cell malignant hematologic diseases

Applied Mathematics and Nonlinear Sciences

This work is licensed under the Creative Commons Attribution 4.0 International License.

In the therapeutic field of T-cell lymphoma/leukemia, long-term efficacy has not yet reached a satisfactory level, especially for relapsed refractory T-cell...

Experimental study of CD4-CART cells for the treatment of CD4-positive T-cell malignant hematologic diseases

Publié en ligne: 26 févr. 2024

Pages: -

Reçu: 02 janv. 2024

Accepté: 07 janv. 2024

DOI: https://doi.org/10.2478/amns-2024-0334

Mots clés
CART, CD4, T cells, Antibody, Malignant hematologic diseases

© 2024 Pengyang Zang, published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Experimental study of CD4-CART cells for the treatment of CD4-positive T-cell malignant hematologic diseases

Publié en ligne: 26 févr. 2024

Pages: -

Reçu: 02 janv. 2024

Accepté: 07 janv. 2024

DOI: https://doi.org/10.2478/amns-2024-0334

Mots clésCART, CD4, T cells, Antibody, Malignant hematologic diseases

© 2024 Pengyang Zang, published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Mots clés
CART, CD4, T cells, Antibody, Malignant hematologic diseases